Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 5, 2003, Pages

  Ryšavá, Romana ^a   Merta, M ^a   Spicka I ^a   Tesar V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

AA amyloidosis; AL amyloidosis; Amyloid; ASCT; DMARDs; Immunotherapy

Indexed keywords

4' IODOESORUBICIN; AMYLOID; ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; MELPHALAN; METHOTREXATE; PREDNISONE; SULFATE; TRANSFER FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AMYLOIDOSIS; ARTICLE; AUTOTRANSPLANTATION; BRONCHIECTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG MECHANISM; HEART INFARCTION; HUMAN; IMMUNOTHERAPY; OSTEOMYELITIS; PASSIVE IMMUNIZATION; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; RHEUMATIC DISEASE; STANDARD; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT PLANNING; VACCINATION;

ADULT; AGED; AMYLOID; AMYLOIDOSIS; COHORT STUDIES; COMBINED MODALITY THERAPY; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041310012     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59
2. Hazenberg BPC, VanRijswik MH. Clinical and therapeutic aspects of AA amyloidosis. Baillières Clin Rheumatol 1994; 8: 661-668
3. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26: 267-285.
4. Garceau D, Gurbindo C, Laurin J. Safety, tolerability and pharmacokinetic profile of Fibrilex (anti-AA amyloid agent) in healthy and renal impaired subjects. In: Apathy D, ed. Amyloid and Amyloidosis. Hungary: 2001: 116-118.
5. Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995; 32: 60-79
6. Comenzo RL, Vosburgh E, Falk RH. Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-3670
7. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25: 465-470
8. Juturi J, Lutton S, Murphy B et al. Therapy with TNF-r Enbrel for amyloidosis (AL); a follow up report. Blood 2000; 96: 166a
9. Lacy MQ, Wettstein P, Dispenzieri A et al. Dendritic cell-based idiotype vaccination for primary systemic amyloidosis. Blood 2000; 96: 164a
10. Merlini G, Lechuga MJ, Anesi E et al. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin. In: Amyloid and Amyloidosis. The Parthenon Publishing Group, Pearl River, New York: 1998: 108-110
11. Kyle RA, Gertz MA, Greipp PR et al. Long-term survival (10 years or more) in 30 patients with primary (AL) amyloidosis. In: Amyloid and Amyloidosis. The Parthenon Publishing Group, Pearl River, New York: 1998: 151-153
12. Gillmore JD, Apperley JF, Craddock C et al. High-dose melphalan and stem cell rescue for AL amyloidosis. In: Amyloid and Amyloidosis. The Parthenon Publishing Group, Pearl River, New York: 1998: 102-104
13. Comenzo R, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282